Will add more tomorrow morning.
About CFMS Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy. Technicals Bullish Gartley pattern (786 retracement) Fibonacci...
NYSE:IQV Is present a nice low risk entry right here at the 50 day moving average. I like this for a possible swing trade.
Will have a serious drop soon. But it's all the set up for the bullish BAT pattern guys.
SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking...
Potential downside breakout for biotech. Still too early to confirm whether it's real or a fake, keep an eye on this one. Entered 25% position so far, will look to add more if further confirmation appears.
We are waiting the macd and aron cross bull signal, please look the yellow circles, and the break out of the triangle chart... atr daily time frame is in the bull territory... we will see...
There is a good RRR to enter XBI today. We seem to be in a bullish channel (showed in chart). IMMU - Which is 1.5% of the sector, is also a good option. (higher risk - higher reward).
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...
... for a 1.04/contract credit. Metrics: Max Profit: $104/contract Max Loss/Buying Power Effect: $196/contract Break Evens: 76.96/93.04 Delta/Theta: -2.95/1.41 Notes: Back into biotech, collecting one-third the width of the wings. Will look to manage the trade at side approaching worthless (i.e., rolling toward the tested side) with a profit target of 50% max.
Biotech needs to hold $85.3(23.6% Fib retracement). Or next support will be 82.5 or 79.0 $XBI $SPY $LABD $LABU
Pictured here is an INDA (66/29) short strangle in the June cycle set up around the 25 delta strikes. Paying 1.00 at the mid, it has break evens of 32.00/39.00, a buying power effect of 5.65, and delta/theta metrics of .68/1.98. Unfortunately, it doesn't have the tightest markets, so expect a little price discovery should you want to get a fill. On the...
... for a 1.67/contract credit. Metrics: Max Profit: 1.67 ($167) Max Loss/Buying Power Effect: 3.33 ($333) Break Evens: 83.33/99.67 Delta: -2.03 Theta: 2.02 Notes: Some nondirectional premium selling here in an exchange-traded fund with high implied (24.8%) relative to the broad market; going 25 delta with the shorts, five-wide with the longs and collecting...
Slow down in China and Europe, Recession in Germany, Trade tension between US/China, Fed capitulation, Bear market rally exceeding 40% from lows, etc., etc., etc... all seem to point towards another leg down, possibly beyond previous lows. Over excitement by the bulls after yesterday's rally adds to my conviction that we may be heading lower, and possibly much...